Forward-Looking Statements and Non-GAAP Financial Information

Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2021 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

This presentation contains GAAP and certain non-GAAP financial measures. Non-GAAP financial measures are adjusted for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses and other specified items presented in AbbVie’s reconciliation tables. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available in the appendix to this presentation and on the company’s website at www.abbvieinvestor.com.

Today’s discussions and presentation are intended for the investor community only; materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.
AbbVie is a Diversified Biopharmaceutical Company with Multiple Sources of Growth

<table>
<thead>
<tr>
<th>Immunology</th>
<th>Oncology</th>
<th>Neuroscience</th>
<th>Aesthetics</th>
<th>Eye Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best-in-Class medicines position AbbVie for sustained leadership; Significant growth potential for Skyrizi and Rinvoq</td>
<td>Large, established position in blood cancer; Building a broad pipeline across a range of cancers for long-term growth</td>
<td>Positioned for significant growth with attractive commercial opportunities across Migraine, Psychiatry Neuro-Degeneration</td>
<td>Leadership positions across core areas; New products, increasing penetration, and global expansion drive significant long-term growth</td>
<td>Large franchise with investment opportunities to sustain leadership; Drive growth through internal and external innovation</td>
</tr>
</tbody>
</table>

Clear Path to Long-Term Growth Following U.S. Humira LOE; Expect Return to Strong Top-Line Growth in 2025, with High-Single Digit CAGR Through Remainder of Decade
A Unique Investment Opportunity With Strong Cash Flow to Support Capital Allocation Priorities

- Compelling capital allocation philosophy, balanced between supporting growth and returning capital to shareholders
- Continued R&D investment in promising, innovative science across therapeutic categories, as well as capacity to pursue additional pipeline assets to augment the internal pipeline
- Committed to a robust and growing dividend; **Increased quarterly dividend by 270% since inception**
- Continued debt repayment to extinguish incremental debt associated with Allergan transaction by end of 2023; **Expect to pay another $4B in maturities in 2023, bringing cumulative debt pay down to ~$34B**
Immunology

Outstanding Execution of Strategy to Transform AbbVie Immunology From a Single Product to a Portfolio Of Differentiated Therapies

<table>
<thead>
<tr>
<th>RHEUM</th>
<th>DERM</th>
<th>GASTRO</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>PsO</td>
<td>CD</td>
</tr>
<tr>
<td>PsA</td>
<td>AD</td>
<td>UC</td>
</tr>
<tr>
<td>AS / nr-axSpA</td>
<td>HS</td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td>Vitiligo</td>
<td>VITAMIN A</td>
</tr>
<tr>
<td>GCA</td>
<td>Alopecia</td>
<td>Alopecia</td>
</tr>
</tbody>
</table>

| Currently Approved | Under Regulatory Review | *Expect to begin Ph3 studies in 2023 |

Early-Stage Immunology Programs

- ABBV-154: Ph2 ongoing in PMR and CD
- Lutikizumab Ph2 ongoing in HS; Plan to begin Ph2 in UC in 2023
- ABBV-668 Ph2 ongoing in CD
- Acazicolcept Ph2 ongoing in SLE
- CUG-252 Ph1 ongoing with plans to develop in SLE
- CLF065 Ph1 ongoing with plans to develop in IBD
Immunology

Skyrizi and Rinvoq Expected to Drive Significant Long-Term Growth

- Adding new indications in 2020-2025 timeframe and ramping to peak share 2025-2030

- Now expect combined risk-adjusted 2025 global sales of >$17.5 billion for Skyrizi and Rinvoq
  - Skyrizi >$10B
  - Rinvoq >$7.5B

- Combined peak sales for Skyrizi and Rinvoq expected to exceed Humira peak revenue (>=$21B) in 2027
Oncology

Established Leader in Hematologic Oncology

Maximize Imbruvica value in the face of increasing market and competitive challenges
- Expected to remain a key asset generating significant cash flow

Strengthen Venclexta’s position in CLL / AML and position for long-term growth by broadening indications
- Expect continued share gains in CLL and AML(unfit); Indication expansion in MM, AML(fit), MDS represent meaningful growth drivers

Expect global oncology revenue to decline to ~$5.7B in 2023 and remain relatively flat through 2024/2025, followed by a return to growth in 2026 as new oncology products and indications ramp
Oncology

Strong Commitment to Advance Pipeline of Innovative Cancer Therapies

Successfully develop and launch new assets to support return to growth for Oncology portfolio

• **Epcoritamab** - potential best-in-class CD3-CD20 bispecific across B cell malignancies; anticipate initial approval in 3L+ DLBCL in 2023*

• **Navitoclax** - potential to improve symptoms, reverse fibrosis and modify the course of myelofibrosis; anticipate approval in 2024

• **Teliso-V** - potential to become an important new treatment option in non-small cell lung cancer; anticipate approval in 2L+ NSCLC in 2024*

Advance early-stage pipeline of novel heme and solid tumor assets to support sustainable, long-term growth

• Focused on **bi-specific, ADC platform** and **next-generation immuno-oncology** approaches

*Anticipate Accelerated Approval based on registration-enabling Ph2 trials
## Oncology

### Compelling Oncology Pipeline Expected to Drive Growth Over Long-Term

<table>
<thead>
<tr>
<th>Phase 3 / Phase 3 Ready</th>
<th>Heme-Onc Targets</th>
<th>Solid Tumor Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proof of Concept in 2022 – 2023</strong></td>
<td>Navitoclax BCL-2 / BCL-xL Inhibitor</td>
<td>Teliso-V e-MET ADC</td>
</tr>
<tr>
<td></td>
<td>Epcoritamab CD3-CD20 Bispecific</td>
<td>ABBV-647** cMET ADC</td>
</tr>
<tr>
<td></td>
<td>ABBV-383* BCMA-CD3 Bispecific</td>
<td>ABBV-637 EGFR BCL-xL ADC</td>
</tr>
<tr>
<td><strong>Proof of Concept in 2024 – 2025</strong></td>
<td>CLBR001/ SWD19 CD19 scAR-T</td>
<td>ABBV-151** GAP9/ TGFβ1</td>
</tr>
<tr>
<td></td>
<td>Effuzu TRAIL Agonist</td>
<td>TTX-030 CD39</td>
</tr>
<tr>
<td></td>
<td>ABBV-744 BET Inhibitor</td>
<td>ABBV-400 cMET ADC</td>
</tr>
<tr>
<td></td>
<td>ABBV-453 BCL-2 Inhibitor</td>
<td>ABBV-706 SE26 ADC</td>
</tr>
<tr>
<td></td>
<td>ABBV-319 CD19 Steroid ADC</td>
<td>ABBV-514 CCR8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ABBV-CLS-579/484 PTPN2</td>
</tr>
</tbody>
</table>


Neuroscience

Leading Portfolio with Options for Every Patient Across the Migraine Spectrum

Acute Migraine Treatment

- Leading treatment for migraine attacks providing rapid and sustained pain relief, with convenient dosing
- Expect >$1B in peak sales

Migraine Prevention

- Approved for episodic migraine; chronic migraine under regulatory review
- Expect peak sales of >$1B

- A unique foundational treatment for prevention of chronic migraine
- Development ongoing for potential expansion into episodic migraine
Neuroscience

Developing Innovative Therapies for Mood, Thought and Anxiety Disorders

• Versatile atypical antipsychotic that provides strong efficacy across multiple symptoms, with minimal impact on weight, lipids and fasting blood glucose

• Recently approved as an adjunctive treatment for major depressive disorder, offering an optimal combination of powerful efficacy and trusted tolerability

• Now expect Vraylar peak revenue of approaching $5B
## Neuroscience

Advancing an Innovative Pipeline for Neuro-Degenerative Diseases

<table>
<thead>
<tr>
<th>Parkinson’s Disease</th>
<th>Alzheimer’s Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>• <strong>ABBV-951</strong> is a potentially transformative improvement to current treatment options for patients with advanced Parkinson’s disease; Regulatory approvals anticipated in 2023; Expect peak sales of &gt;$1B</td>
<td>• R&amp;D focused on optimized a-beta antibody approaches in Alzheimer’s disease for faster amyloid clearance with low ARIA and patient friendly dosing regimen, as well as clearing intracellular tau aggregates and modulating neuroinflammatory response</td>
</tr>
<tr>
<td>• Discovery efforts focused on preventing spread of Lewy bodies, removing existing aggregates, and restoring cellular function</td>
<td>• Recently began Ph2 study in AD for lead a-beta antibody, ABBV-916</td>
</tr>
</tbody>
</table>
Aesthetics

Market Leader in Global Aesthetics with Significant Growth Opportunities from New Product Introduction, Increasing Market Penetration and Global Expansion

$14B Global Market with Low Consumer Penetration and Significant Growth Potential

Market Leading Positions in Key Aesthetics Categories

— BOTOX COSMETIC — JUVÉDERM

Strategic Investments Drive Growth

• Sustained investment in consumer acquisition and retention
• Enhanced digital products & services through Alië loyalty program
• Best-in-class injector training program to grow base of skilled providers
• International expansion to develop high growth markets including China, Japan and Latin America

Continued Innovation through R&D Programs and Business Development

• Innovative Toxin Pipeline: Short- and long-acting toxins
• Dermal Filler Expansion: Bio-stimulatory and regenerative fillers
• Body Contouring: Soliton for cellulite and CoolSculpting enhancements

Expect Global Aesthetics sales of >$9B in 2029

Source: Medical Insight, Inc. Global Aesthetic Market Study November 2021 and AbbVie data.
Eye Care

Strong Foundation with Broad Portfolio Across Retina, Glaucoma, Refractive, Dry Eye and Consumer Eye Care Generates Significant Cash Flow for Investment

**Eye Care Portfolio**

**Key Focus and Priorities:**

<table>
<thead>
<tr>
<th><strong>Eye Care Portfolio</strong></th>
<th><strong>Key Focus and Priorities:</strong></th>
</tr>
</thead>
</table>
| **RETINA**             | - Enhance standard-of-care in chronic retinal conditions with RGX-314, a potential one-time gene therapy  
                        | - Establish new treatments in geographic atrophy and explore vision restoration |
| **GLAUCOMA**           | - Optimize drop-free interventions (Durysta, Xen, Prostamide 408 SR)  
                        | - Explore neuroprotective MOAs to preserve and regenerate the optic nerve |
| **DRY EYE**            | - Improve standard of care through pursuit of differentiated MOAs (AGN-242428 RORγ) and novel sustained release platforms |
| **REFRACTIVE**         | - Explore novel topical drops to provide enhanced benefits for presbyopia  
                        | - Pursue next-generation corneal regenerative therapies |
| **CONSUMER**           | - Innovate Artificial Tears with novel ingredients and new presentations  
                        | - Expand into adjacent areas (e.g., allergy, ocular health) |
Innovation-Driven R&D Organization

Proven Track Record of Developing New Medicines That Consistently Elevate the Standard of Care

- 240+ Clinical Trials
- 5 Core Therapeutic Areas
- 13K+ R&D Employees
- 80+ Clinical Programs
- ~50 New Molecular Entities
- 75+ Conditions Treated
- 25 Major Product or Indication Approvals*
- 110+ New Study Starts Planned for 2023

*Reflects approvals since 2013
AbbVie Pipeline

### Phase 1
- CUG-252* (IL-2 Mutein) SLE
- CLF065* (Glp-2 agonist) IBD
- ABBV-151 (GARP+TGF[β]1) Solid Tumors
- ABBV-400 (cMet ADC) NSCLC
- ABBV-647* (PTK7 ADC) NSCLC
- ABBV-637 (EGFR BCL-2xL ADC) NSCLC
- ABBV-706 (SEZ6 ADC) SCLC
- ABBV-151 (GARP+TGF[β]1) Solid Tumors
- ABBV-400 (cMet ADC) NSCLC
- ABBV-647* (PTK7 ADC) NSCLC
- ABBV-637 (EGFR BCL-2xL ADC) NSCLC
- ABBV-706 (SEZ6 ADC) SCLC
- ABBV-181 (PD-1) Solid Tumors
- ABBV-927 (CD40) Solid Tumors
- JAB-3312* (SHP2) Solid Tumors
- TTX-030* (CD39) Solid Tumors
- ABBV-CLS-579* (PTPN2) Solid Tumors
- ABBV-CLS-454* (PTPN2) Solid Tumors
- ABBV-514 (CCR8) Solid Tumors
- Eftozza (TRAIL) Heme Tumors
- ABBV-319 (CD19/Steroid ADC) Heme Tumors
- ABBV-525 (MALT1) Heme Tumors
- CLBR001/SWI019* (sCAR-T) Heme Tumors
- ABBV-383 (CD3-BCAM) MM
- HPN-217* (CD3-BCAM) MM
- ABBV-453 (BCL-2) R/R MM t(11;14)
- ABBV-744 (BET) MF
- ABBV-552 (SV2A) Alzheimer’s Disease
- ABBV-CLS-7262* (eIF2B) Multiple Neuro
- AGN-241622 (Alpha2) Presbyopia
- ABBV-1882 (anti-PDI) HIV
- ABBV-903 (MPro Inhibitor) COVID

### Phase 2
- ABBV-154 (TNF-Steroid ADC) PMR
- ABBV-154 (TNF-Steroid ADC) CD
- Rinvoq (JAK 1) Vitiligo
- Rinvoq (JAK 1) SLE
- Rinvoq (JAK 1) HS
- Acizolcept ALPN-101* (JCSO/CD28) SLE
- LuLizumab (IL-1α/1β) HS
- ABBV-668 (RIPK1) UC
- ABBV-CX-20B9* (CD71) Solid/Heme Tumors
- ABBV-916 (α-βeta) Alzheimer’s Disease
- Botox (SNARE) Essential Tremor
- Elezanumab (RGMa) Stroke
- Elezanumab (RGMa) SCI
- AL002* (TREM2) AD
- Onabota X (SNARE) Glioblastoma Lines
- Onabota X (SNARE) Forehead Lines
- AGN-242428 (ROR) Dry Eye
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-199408 (Prostamide 408 SR) Glaucoma
- CF Triple Combo (CETR-CL/CETR-C2/CETR-P)
- Armour Thyroid (T3T4) Hypothyroidism
- AGN-151607 (SNARE) Atrial Fibrillation
- Botox (SNARE) IC/IPS

### Registrational / Phase 3
- Rinvoq (JAK 1) GCA
- Skyrizz* (IL-23) UC
- Imbruvica* (BTK) 1L FL
- Imbruvica* (BTK) R/R MCL
- Venclexta* (BCL-2) R/R MCL
- Venclexta* (BCL-2) AML Maintenance
- Venclexta* (BCL-2) R/R MM t(11;14)
- Venclexta* (BCL-2) R/R High Risk MDS
- Navitoclax (BCL-2/BCL-xL) Myelofibrosis
- Epicoritamab* (CD3-CD20) 1L DCLBL
- Epicoritamab* (CD3-CD20) R/R DCLBL
- Epicoritamab* (CD3-CD20) R/R FL
- Telisio-α* (cMet ADC) NSCLC
- Botox (SNARE) Episodic Migraine
- BoNT/E (SNARE) Glioblastoma Lines
- Botox (SNARE) Maxeter Prominence
- Botox (SNARE) Platsysma Prominence
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- Aztreonam/Avlactam* (PBP3) Infection

### Submitted
- Rinvoq (JAK 1) CD
- Epicoritamab* (CD3-CD20): R/R DCLBL
- ABBV-951 (dopamine receptor) PD
- Qulipta (CGRP) Chronic Migraine Prevention

---

*Partnered assets; See appendix for partnership summary

As of January 10, 2023
Excludes devices in development

---

*Not for promotional use*
## Anticipated Key Pipeline Events

<table>
<thead>
<tr>
<th>Regulatory Approvals</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rinvoq CD</td>
<td></td>
<td>Teliso V 2L+ NSCLC (AA)</td>
</tr>
<tr>
<td>Epcortitamab 3L R/R DLBCL (AA)</td>
<td></td>
<td>Botox Platysma</td>
</tr>
<tr>
<td>ABBV-951 Advanced PD</td>
<td></td>
<td>Botox Masseter</td>
</tr>
<tr>
<td>Qulipta Chronic Migraine Prevention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory Submissions</td>
<td></td>
<td>Rinvoq GCA</td>
</tr>
<tr>
<td>Skyrizi UC</td>
<td></td>
<td>Teliso-V NSCLC</td>
</tr>
<tr>
<td>Venclexta 3L+ MM w/ t(11;14)</td>
<td></td>
<td>Venclexta High Risk MDS</td>
</tr>
<tr>
<td>Navitoclax 1L MF</td>
<td></td>
<td>Navitoclax r/r MF</td>
</tr>
<tr>
<td>Botox Platysma</td>
<td></td>
<td>Botox Episodic Migraine</td>
</tr>
<tr>
<td>Botox Masseter</td>
<td></td>
<td>BoNT/E (Short-Acting Toxin) Glabellar Lines</td>
</tr>
<tr>
<td>Ph3/Registrational Data Readouts</td>
<td></td>
<td>Rinvoq Ph3 GCA</td>
</tr>
<tr>
<td>Skyrizi UC Induction/Maintenance</td>
<td></td>
<td>Venclexta Ph3 High Risk MDS</td>
</tr>
<tr>
<td>Venclexta Ph3 3L+ MM t(11;14) (CANOVA)</td>
<td></td>
<td>Navitoclax Ph3 r/r MF (Transform-2)</td>
</tr>
<tr>
<td>Navitoclax Ph3 1L MF (Transform-1)</td>
<td></td>
<td>Botox Ph3 Episodic Migraine</td>
</tr>
<tr>
<td>Epcortitamab Ph3 3L DLBCL</td>
<td></td>
<td>ABBV-RGX-314 Ph3 wAMD SR</td>
</tr>
<tr>
<td>Teliso-V Ph2 2L+ NSCLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Botox Ph3 Masseter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Botox Ph3 Platysma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BoNT/E (Short-Acting Toxin) Ph3 Glabellar Lines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early / Mid Stage Data Readouts</td>
<td></td>
<td>ABBV-154 (TNF-Steroid ADC) Ph2 CD Induction</td>
</tr>
<tr>
<td>Rinvoq Vitiligo</td>
<td></td>
<td>Lutikizumab (IL-1c/1f) Ph2 HS</td>
</tr>
<tr>
<td>ABBV-154 (TNF-Steroid ADC) Ph2 PMR</td>
<td></td>
<td>ABBV-CLS-579 (PTPN2) Ph1 Solid Tumors</td>
</tr>
<tr>
<td>TTX-030 (CD39) Ph1 Solid Tumors</td>
<td></td>
<td>ABBV-CLS-484 (PTPN2) Ph1 Solid Tumors</td>
</tr>
<tr>
<td>CLBR001/SW019 (CD19 sCAR-T) Ph1 Heme Tumors</td>
<td></td>
<td>ABBV-400 (c-Met ADC) Ph1 Solid Tumors</td>
</tr>
<tr>
<td>Eftoza (Trofil) Ph1 Heme Tumors</td>
<td></td>
<td>ABBV-453 (BCL-2) Ph1 MM t(11;14)</td>
</tr>
<tr>
<td>ABBV-637 (EGFR BCL-xLi ADC) Ph1 NSCLC</td>
<td></td>
<td>ABBV-744 (BET) Ph1 Mf</td>
</tr>
<tr>
<td>AGN-241622 (Alpha2) Presbyopia</td>
<td></td>
<td>Elezanumab (RGMa) Ph2 Stroke</td>
</tr>
<tr>
<td>ABBV-552 (SV2A) Ph2 AD Cognition</td>
<td></td>
<td>ABBV-CLS-7262 (eIF2B) Ph2 ALS</td>
</tr>
</tbody>
</table>

As of January 10, 2023
AA = Accelerated Approval
AbbVie: A Unique Investment Opportunity Poised for Continued Strong Shareholder Returns

- Portfolio of leading brands in attractive and sustainable markets

- Pipeline of innovative, highly differentiated assets to address significant unmet needs, with potential to drive significant growth

- Compelling capital allocation philosophy balanced between supporting growth and returning capital to shareholders

- Track record of strong execution, consistently meeting or exceeding financial commitments to deliver industry leading financial performance

A unique investment vehicle, offering top-tier revenue and EPS growth, significant cash flow and strong return of capital to shareholders
AbbVie’s Partnered Assets

- ABBV-2029 developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option for additional development
- ABBV-647 developed in cooperation with Pfizer
- ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie
- Acazicolcept (ALPN-101) developed by Alpine Immune Sciences through current Phase 2 study and AbbVie holds option for additional development
- AL002 developed by Alector through Phase 2 and AbbVie holds option for additional development
- Aztreonam/Avibactam co-developed by Pfizer and AbbVie
- CLBR001/SWI019 developed by Calibr in a first-in-patient trial and AbbVie holds option for additional development
- CLF065 developed by Scripps/Calibr in a first-in-patient trial and AbbVie holds option for additional development
- CUG-252 developed by Cugene through Phase 1b and AbbVie holds option for additional development
- Epcoritamab developed in partnership with Genmab
- HPN-217 developed by Harpoon through Phase 1/2 and AbbVie holds option for additional development
- Imbruvica jointly developed with Janssen Biotech
- JAB-3312 developed in partnership with Jacobio
- RGX-314 co-developed by REGENXBIO and AbbVie
- Skyrizi developed in cooperation with Boehringer Ingelheim
- Teliso-V licensed from Seagen and Pierre Fabre
- TTX-030 developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global development
- Venclexta jointly developed with Roche
- Vraylar developed in cooperation with Gedeon Richter